MedTrace Logo

Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise

NCT01561404 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2015-04-28

No results posted yet for this study

Summary

This is an exploratory study based on the hypothesis that kidney transplant patients treated with an immunosuppressive therapy based on an inhibitor of the mammalian target of rapamycin (m-TOR) may increase resistance to physical exercise, which would result in an improvement in the quality of life of these patients.

Conditions

  • Disorder Related to Renal Transplantation
  • Exercise, Aerobic
  • Muscle Strength

Interventions

DRUG

Everolimus

In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.

Sponsors & Collaborators

  • Josep M Cruzado

    lead OTHER

Principal Investigators

  • Josep M. Cruzado, MD · Nephrology Department Hospital Universitari de Bellvitge

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01561404 on ClinicalTrials.gov